Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior

Cost: No fee

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, clinical administrators and healthcare teams.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, and Interprofessional Continuing Education (IPCE) credit.

Webinar Description: Once we’ve successfully managed the organizational and clinical steps to implement treatment for patients with OUD, we need to consider how to best sustain this new service. How do we ensure continued access to high-quality care for our patients, including those with on-going challenges? What does treatment look like for patients on their first visit and follow-up visits? This session will discuss key considerations for patient initiation (induction) and on-going visits, including lab guidelines. We will additionally address the clinical management of patients with continued opioid use, poly-substance use, and comorbid mental health conditions.

Educational Objectives:

• Consider OUD medication selection, including appropriateness of buprenorphine, long-acting injectable naltrexone, and methadone, based on patient assessment and choice
• Determine key considerations for patient initiation visit (induction) and follow up visits, including lab guidelines
• Explain considerations in managing of more complicated cases: continued opioid use, poly-substance use and comorbid conditions

Accreditation and Certification of this activity:

In support of improving patient care, this activity has been planned and implemented by Addiction Technology Transfer Center Network and American Academy of Addiction Psychiatry. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

In 2020, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA), Association for Social Work Boards (ASWB) and American Dental Association (ADA).

Interprofessional Continuing Education (IPCE) Designation Statement:

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education credits for learning and change.

Physician Designation Statement

American Academy of Addiction Psychiatry designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement

American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 Nursing Contact Hours.

PA Designation Statement

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.